Sanger Human Cell Atlasing Project

NCT06497673 | Enrolling By Invitation

• 1 other identifier: 260474
• Study Type: observational
• Target: 4,000
• Locations: 1 country
• Sites: 1

Brief Summary

"Cell Atlasing" refers to a novel strategy to characterise cells in tissues at the molecular level in a quantitative manner. The international Human Cell Atlas consortium brings together a community of biologists, clinicians, technologists, physicists, computational scientists, software engineers, and mathematicians to capitalise on drawing together leaders with various biological, technical and computational expertise. The project is based on the aim to define all human cell types in terms of their distinctive patterns of gene expression, physiological states, developmental trajectories, and location. This will pave the way to create a reference map of all human cells as a basis for understanding human health and diagnosing, monitoring, and treating disease.

Conditions

Human Development; Genetic Disease

Outcome Measures

Primary Outcomes (1)

• This project aims to scale up the single cell genomics and high-throughput highly multiplex spatial gene expression profiling approaches.

  Coupled with powerful computational methods, this strategy will produce a comprehensive and systematic reference map of human cells, providing a fundamental blueprint of cell states for both basic biological research and clinical practice.

  10 years

Interventions

sample collection OTHER

New collected samples, as well as surplus surgical and diagnostic samples.

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Samples are from the living and the deceased age 0 to 99+ from healthy and diseased individuals, to facilitate atlasing of the entire human body. Samples for this study will be obtained from tissue banks and ethically approved research studies where consent has been taken for use of the samples in future research. Prospective samples will also be collected via collaborators at NHS sites. This will allow for the collection of all cell types to fulfil the aims of the study. We will provide collaborators with study specific participant information sheets and informed consent forms to recruit potential donors.

You may qualify if:

• Samples are from the living and the deceased age 0 to 99+ from healthy and diseased individuals.
• All samples will have fully informed consent for use in research.

You may not qualify if:

• Samples taken without consent for use in future research
• Samples taken from individuals without the capacity to consent to use in research

Sponsors & Collaborators

• The Wellcome Sanger Institute: lead

Study Sites (1)

Wellcome Sanger Institute

Cambridge, United Kingdom

Location

Biospecimen

Retention: SAMPLES WITH DNA

Samples will include whole or dissected tissues, frozen or fixed samples, single cell suspension and/or purified nucleic acids. Peripheral blood mononuclear cells (PBMCs), primary human umbilical vein endothelial cells (HUVEC), whole blood, bone marrow, urine, tissue samples and cell lines. Fetal samples will be received up to 24 weeks post conception.

MeSH Terms

Conditions

Genetic Diseases, Inborn

Interventions

Specimen Handling

Condition Hierarchy (Ancestors)

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Intervention Hierarchy (Ancestors)

Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Investigative Techniques

Study Officials

• Sarah Teichmann

  Wellcome Sanger Institute

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 4, 2024
• First Posted: July 12, 2024
• Study Start: December 16, 2019
• Primary Completion (Estimated): November 7, 2029
• Study Completion (Estimated): November 7, 2029
• Last Updated: July 12, 2024

Record last verified: 2024-07

Locations

GB (1)